Vitamin D receptor polymorphisms and prostate cancer

Molecular Carcinogenesis

Volumn 27, Issue 1, 2000, Pages 18-23

  Blazer III, Dan G ^a   Umbach, David M ^a   Bostick, Roberd M ^a,c   Taylor, Jack A ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Epidemiology; Polymorphism; Prostate cancer; Vitamin D; Vitamin D receptor

Indexed keywords

CALCITRIOL; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GENE LINKAGE DISEQUILIBRIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VITAMIN BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; EXONS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NORTH CAROLINA; POLY A; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK FACTORS;

PIERINAE;

EID: 0033964655     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(200001)27:1<18::AID-MC4>3.0.CO;2-O     Document Type: Article

References (35)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10:1307-1311.
3. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-1960.
4. Peehl DM, Skowronski RJ, Leung GK, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-810.
5. Schwartz GG, Oeler TA, Uskokovic MR, et al. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 1994;14:1077-1081.
6. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995; 136:20-26.
7. Miller GJ, Stapleton GE, Hedlund TE, et al. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1a-,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1: 997-1003.
8. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999-1006.
9. Schwartz GG, Wang MH, Zang M, et al. 1alpha, 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997;6:727-732.
10. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: A prediagnostic study with stored sera [see comments]. Cancer Epidemiol Biorrarkers Prev 1993;2: 467-472.
11. Braun MM, Helzlsouer KJ, Hollis BW, et al. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, Urvted States). Cancer Causes Control 1995;6: 235-239
12. Gann PH, Ma J, Hennekens CH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5:121-126.
13. Gross C, Stamey T, Hancock S, et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159:2035-2039.
14. Hedlund TE, Moffatt KA, Miller GJ. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1 : Evidence that the antiproliferative effects of 1alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 1996;137:1554-1561
15. Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58: 277-288.
16. Zhuang SH, Schwartz GG, Cameron D, et al. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997;126: 83-90.
17. Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1alpha,25-dihydroxyvitamin D3. Cancer Res 1992;52:515-520.
18. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13: 325-349.
19. Morrison NA, Yeoman R, Kelly PJ, et al. Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci U S A 1992;89:6665-6669.
20. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles [see comments]. Nature 1994;367:284-287.
21. Ingles SA, Haile RW, Henderson BE, et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: Implications for association studies. Cancer Epidemiol Biomarkers Prev 1997;6: 93-98.
22. Taylor JA, Hirvonen A, Watson M, et al. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108-4110.
23. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor [see comments]. J Natl Cancer Inst 1997;89:166-170.
24. Riggs BL, Nguyen TV, Melton LJ, 3rd, et al. The contribution of vitamin D receptor gene alleles to the determination of bone mineral density in normal and osteoporotic women. J Bone Miner Res 1995;10:991-996.
25. Weir BS. Genetic data analysis II. Sunderland, MA: Sinauer Associates, Inc. Publishers, 1996.
26. Terwilliger JD, Ott J. Linkage disequilibrium between alleles at marker loci. Handbook of human genetic linkage. Baltimore: The Johns Hopkins University Press, 1994, p 188-198.
27. Breslow NE, Day NE. Statistical methods in cancer research, Vol 1: The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980.
28. Hosmer DW, Lemeshow S. Applied logistic regression New York: John Wiley, 1989.
29. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998;7:385-390.
30. Ingles SA, Coetzee GA, Ross RK, et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998;58:1620-1623.
31. Kinyamu HK, Gallagher JC, Knezetic JA, et al. Effect of vitamin D receptor genotypes on calcium absorption, duodenal vitamin D receptor concentration, and serum 1,25 dihydroxyvitamin D levels in normal women. Calcif Tissue Int 1997;60:491-495.
32. Carling T, Rastad J, Akerstrom G, et al. Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J Clin Endocrinol Metab 1998;83: 2255-2259.
33. Mocharla H, Butch AW, Pappas AA, et al. Quantification of vitamin D receptor mRNA by competitive polymerase chain reaction in PBMC: lack of correspondence with common allelic variants. J Bone Miner Res 1997;12: 726-733.
34. Verbeek W, Gombart AF, Shiohara M, et al. Vitamin D receptor: No evidence for allele-specific mRNA stability in cells which are heterozygous for the Taq I restriction enzyme polymorphism. Biochem Biophys Res Commun 1997;238: 77-80.
35. Gross C, Musiol IM, Eccleshall TR, et al. Vitamin D receptor gene polymorphisms: Analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. Biochem Biophys Res Commun 1998;242:467-473.